This observational study is analyzing DNA from blood and tissue samples of people with newly diagnosed primary lung cancer. Researchers are looking for changes in DNA, called genetic polymorphisms, that might be linked to lung cancer risk. They are also studying how factors like gender, age, and diet might interact with these genetic changes. The goal is to better understand lung cancer and identify potential biomarkers (biological signs) for future research. This study is open to individuals aged 18 to 120 years old who have been newly diagnosed with primary lung cancer at Massachusetts General Hospital (MGH) or Boston Medical Center Cancer Center. The main goal is to assess metabolic polymorphisms over a 10-year period.

Study design

This is an observational study that began as a case-control study and is now case-only. The planned enrollment is unknown.

What's involved

Blood samples are collected from participants. Tissue samples may also be collected if you are undergoing surgery.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, metabolic polymorphisms, will be measured at 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.